Friday, 18 December 2020

Lupine Publishers | Effects of Kav001 (A Kavain Analogue) on LPS-Induced Cytokines and Neutrophil Infiltration

 Lupine Publishers | LOJ Pharmacology & Clinical Research


Abstract

Background: TNF-α, a cytokine, is known to be involved in LPS-induced inflammation. Our recent data indicate that treatment of Kavain in mouse or human cells significantly suppresses TNF-α production in response to LPS. In order to completely identify one Kavain analogue (Kav001) reported in our previous data, we further analyzed its biological function in this paper.

Methods and Results: Commercial Kavain or Kav001 as inhibitor was used. ELISA was performed for detection of TNF-α, IL-1β, IL-6, IL-4, or Caspase 1 after treatment of THP-1 cells with Kav001. Wild type mice (C57BL/6) were used for neutrophil infiltration assay. A kinase/protein array was performed to analyze if Kav001 affects any kinases/protein in response to LPS. Conclusions: It is clear that Kav001 not only inhibits TNF-α, but also IL-1β, IL-6, caspase 1 and neutrophil infiltration in response to LPS compared to control.

Introduction

Kavain is known as a treatment for certain diseases [1-3]. Amar’s group recently reported that, in vivo, Kavain mediated alveolar bone loss and inflammatory infiltrate in a mnouse model [4]. Kavain is found to affect TNF-α production through regulation of NF-kB [5] and to be inhibited by ERK2 dephosphorylation in vitro or in vivo [6]. Our previous data indicate that Kavain inhibits P. gingivalis/LPS-induced inflammation/inflammatory disease [7,8]. Recently, we found that Kavain grants small amounts of toxicity to mammalian cells, most likely due to its insoluble chemical structure with hydrophobicity. To address this issue, we designed and synthesized compounds with the basic chemical structure of Kavain with a different number of hydrophilic bonds. One soluble compound (named Kav001) from the Kavain analogue was selected and further confirmed to have a stronger biological function than Kavain by in vitro/in vivo experiments such as CAIA mouse models or endotoxic shock [9]. In this paper, we further found that Kav001 not only inhibits TNF-α, but also IL-1β, IL-6, caspase 1 and neutrophil infiltration. However, this phenomenon cannot be observed when macrophages are treated with LPS plus Kavain. We believe that Kav001 may mediate a novel link between Kav001 and LPS-induced inflammation and may be used as a key inhibitor to LPS-induced inflammation/inflammatory disease.

Materials and Methods

Animals and cells

Wild type mice (8-10 week-old C57BL/6, Jackson Labs) were maintained under strict specific pathogen-free (SPF) conditions. All protocols were approved by the Boston University Institutional Animal Care and Use Committee and were performed in compliance with the relevant animal care and use laws and institutional guidelines. THP-1 cells (TIB-202, ATCC) were cultured in a RPMI- 1640 media (Cat#: 11875–093, Life Technologies, NY) with 10% FBS at 37 °C in a 5% CO2 atmosphere.

Compounds

Commercial Kavain (Cat#59780, Sigma‐Aldrich Co., Natick, MA) and custom synthesized analogue Kav001 (Lot#KB180125, KareBay Biochem, Inc.) were obtained. The analysis of each compound shows that ≥95% purity. The stock concentration of each compound was prepared with 10μg/μl. The compound was diluted to 100μg/ml in 25% DMSO for Kavain or in water for Kav001 just before the experiment.

Elisa

The treated media from THP-1 cells were subjected to ELISA for TNF-α detection with the kit (Cat#: ab181421, Abcam), IL-1β detection with the kit (Cat#: ab100562, Abcam), IL-6 detection with the kit (Cat#: KHC0061, Life technologies), IL-4 detection with the kit (Cat#: BMS225-2, Thermo Fisher), or Caspase 1 (Cat#: ab219633, Abcam). ELISA immunoreactivity was measured by a reader (Model 680, Bio-Rad). The data were graphed.

Neutrophil Infiltration Assay

Mice (n=3) were untreated or treated by i.p. injection of E.coli LPS (1mg/kg body weight) and/or oral gavage of Kav001 (30mg/ kg) for 24hrs. Skin tissues from each group were taken and fixed in 4% paraformaldehyde, then embedded in O.C.T. compound [10,11]. Skin sections (5μm) were made and stained with H&E (hematoxylin and eosin). Results were analyzed and imaged.

Protein Array

1 × 105 THP-1 cells were treated with 100μg/ml of E. coli LPS (Sigma) or plus Kav001 (0.1mg/ml) for 16 hrs at 37 °C. The medium from each test was centrifuged at 1,500 × g and then treated with a specific kit for human protein cytokine array (RayBiotech, Norcross, GA) based on the manufacturer’s instructions. The data were analyzed using a Verrado Imaging System (Bio-Rad) and graphed.

Statistical Analysis

All tests were done in triplicate and statistical analyses were done with the SAS software package. All data were normally distributed. For multiple mean comparisons, we conducted ANOVA analysis by the Student’s t-test for single mean comparison. P values less than 0.05 were considered significant.

Results

In order to examine whether Kav001 also inhibits other cytokines besides TNF-α, we made a relevant experiment via ELISA. As shown in Figure 1A-1C, co-treatment of LPS plus Kav001 (A-C, #4) significantly reduces LPS-induced TNF-α, IL-1β, or IL-6 compared to the positive controls (A-C, #2). This phenomenon for detection of TNF-α was also observed while co-treatment of LPS plus Kavain but was not detectable for IL-1β or IL-6 production (1B&C, #3) As shown in Figure 1D,1B. Additionally, neither Kavain nor Kav001 was found to affect IL-4. Because our preliminary data indicate that Kav001 affects some cytokines in response to LPS, we were therefore interested in whether Kav001 is involved in other stimuli-mediated cytokines. As shown in Figure 1E & 1G, Kav001 strongly reduced all three stimuli-induced cytokine productions, TNF-α (E, No.4), IL-1β (F, No.4), and IL-6 (G, No.4) compared to their positive control (No.2 of E, F, or G). This phenomenon for reduction of IL-1β (F, No.3) or IL-6 (G, No.3) was not observed with co-treatment of stimuli plus Kavain. Since it is known that caspase 1 expression is activated with TNF-α, IL-1 beta, or IL-6 [12-14], we wanted to further test whether Kav001 inhibits caspase 1 caused by TNF-α, IL-1 beta, or IL-6. As shown in Figure 1F & 1H, Kav001 (H, No.6) reduced LPS-induced caspase 1 compared to the positive control (H, No.2).

As a control, Kavain did not reduce LPS-induced caspase 1, but instead increased its value (H, No.5). In order to analyze whether the treatment of Kav001 affects any kinases/protein upstream of caspase 1 in response to LPS, a kinase/protein array was performed. As shown in Figure 2B & 2C Kav001 significantly reduced LPSinduced kinases such as Akt (Protein kinase B) at 17%, ATM (Ataxia telangiectasia mutated) at 13%, caspase 3 at 11.5%, caspase 7 at 8.6%, CHK1 (Checkpoint kinase 1) at 26.4%, CHK2 (Checkpoint kinase 2) at 15.3%, and ERK1/2 at 12.7%/14.8%, but does not affect p27, p53, or TAK1 (Transforming growth factor beta-activated kinase 1 (Figure 2A & 2D). As it is known that subcutaneous injection of LPS in mice induces neutrophil infiltration of tissues [15,16], we were therefore interested in whether Kav001 treatment is able to suppress LPS-induced neutrophil infiltration. As shown in Figure 3A & 3D, indeed, subcutaneous treatment of 30mg/kg of Kav001 significantly reduced LPS-induced Neutrophil infiltration of tissues in mouse (DI,II, III) compared to the positive control (CI,II, III).

Figure 2:Kinase/Protein array. (A) The stamped identification number on the array. (B) THP-1 cells were untreated or treated with LPS alone or LPS+ Kav001 over night. The conditioned medium from each test group was assessed by protein assay and quantified by a Versace Imaging System. (C) Analysis of the intensity on the array filter. The cell intensity treated by LPS was assigned to 100% as base value and compared to the others. There ratio was calculated in this table.

Discussion

Kavain was shown to affect TNF-α transcriptional regulation [6- 8]. Compared with Kavain, Kav001 not only inhibits LPS-induced TNF-α, , but also IL-1β, IL-6, caspase 1 or Neutrophil infiltration. DMSO is known to be widely used as reagent solvent but sometimes causes a little toxicity to mammalian cells [17]. It is known that Kavain is dissolved in the higher concentration of DMSO (≥25%) while Kav001 is completely dissolved in water. This water-soluble property may be the reason why Kav001 prevent DMSO-mediated toxicity to cells with a longer period of efficacy. Our most recent data support this potential hypothesis [9]. Additionally, neutrophils are the innate immune response and thus, neutrophilic infiltration of tissues is involved in many inflammatory diseases [18,19]. In order to inhibit the neutrophilic infiltration from tissue injury (I/R injury, brain injury, ethanol feeding-induced liver injury), several inhibitors such as MgIG (Magnesium isoglycyrrhizinate), Clenbuterol, Phillyrin, or PAI-1 (Plasminogen activator inhibitor-1) have been widely studied [20,21]. Researcher groups have also suggested that these inhibitors suppress infiltration of neutrophils via regulation of factors such as MyD88 or p38 MAPK [22,23]. However, these studies of certain inhibitors leave several questions, such as whether there is a common key point between their pathways. Our data here also show that the treatment of Kav001 significantly reduces LPS-induced neutrophilic infiltration. Thus, Kav001 may be used for suppression of neutrophil infiltration induced by other stimuli or injuries. Since TNF-α, IL-1β, or IL-6 was found here to be inhibited by Kav001, we assume that Kav001 may have treatment for inflammatory diseases caused by these cytokines (TNF-α, IL-1β, or IL-6). We will try to address this hypothesis for future research.

 

https://lupinepublishers.com/pharmacology-clinical-research-journal/pdf/LOJPCR.MS.ID.000122.pdf

https://lupinepublishers.com/pharmacology-clinical-research-journal/fulltext/effects-of-kav001-(a-kavain-analogue)-on-lps-induced-cytokines-and-neutrophil-infiltration.ID.000122.php

For more Lupine Publishers Open Access Journals Please visit our website: https://lupinepublishersgroup.com/

For more Pharmacology & Clinical Research Please Click
Here: https://lupinepublishers.com/pharmacology-clinical-research-journal/
To Know more Open Access Publishers Click on Lupine Publishers 

Follow on Linkedin : https://www.linkedin.com/company/lupinepublishers
Follow on Twitter   :  https://twitter.com/lupine_online

Lupine Publishers: Lupine Publishers | Acute Primary Herpetic Gingivo...

Lupine Publishers: Lupine Publishers | Acute Primary Herpetic Gingivo...:  Lupine Publishers | Journal of Pediatric Dentistry Abstract This case report describes the management ...

Thursday, 17 December 2020

Monday, 14 December 2020

Friday, 11 December 2020

Lupine Publishers | Genesis, Evaluation and Progression of A Breakthrough Discovery to Efficiently Cure Cancer Through Use of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotics as Adjuvants Along with the Traditional Cancer Therapies, Through Restoration of Healthy and Balanced Intestinal Microbiota and their Microbiome

 Lupine Publishers | LOJ Pharmacology & Clinical Research


Abstract

A breakthrough, Multiple Mixed Strain Probiotic Therapy, although originally designed to cure hospital acquired infections, has been discovered serendipitously by Dr. M.S. Reddy to treat cancer with greatest accuracy (60% as opposed to current 20%), with least or no side effects and least or no relapse, when used as an adjuvant therapy along with standard cancer therapies, including immune checkpoint therapy. This discovery can be further refined and improved to treat cancer at 80 to 100% efficacy to save lives of millions of people in the world by significantly improving immune system through positive manipulation of the human gut microbiota and their microbiome. The results of the clinical trials are outlined along with discussion and conclusion. The references listed have been limited to the latest, significant, and directly applicable research discoveries only.

Keywords: Dr MS Reddy’s multiple mixed strain probiotic therapy to treat hospital acquired infections; Nosocomial infections; Dr MS Reddy multiple mixed strain adjuvant cancer therapy; Microbiota; Hospital acquired infections; Immune checkpoint therapy; C Diff; MRSA; Microbiome

Introduction

A brief history on statistics of the cancer episode in the world. The International agency for Research on Cancer (IARC), a division of The World Health Organization (WHO), estimated that the global cancer epidemic rose to 18.1 million new cases and 9.6 million deaths in 2018 alone. The IARC reports 1 in 5 men (20%) and 1 in 6 women (16.66%) worldwide develop cancer during their lifetime. 1 in 8 men (12.5%) and 1 in 11 women (9.09%) die from the disease. In addition, every sixth death in the world is due to cancer. Assuming world population is 7 billion and assuming the ratio of male to female is 50:50, 700 million men and 583 million women will develop cancer during their life time and 437 million men and 318 million women will die of cancer. These figures are astronomical, mind blowing, and downright scary, unless something is done to prevent or cure cancer efficiently with 100 percent accuracy, without any relapse.

Materials, Methods, and Discussion

The question here is, how did Dr. M.S. Reddy’s discovery to treat cancer came about serendipitously? In the year 2016, Dr. M.S. Reddy, after working extensively for four decades on probiotics, published a breakthrough research article on the usage of Multiple Mixed Strain Probiotic Therapy to treat or prevent the hospital acquired or nosocomial infections caused by Clostridium difficile (C. diff), and Methicillin Resistant Staphylococcus Aureus (MRSA) [1-4]. He has isolated and selected the strains of Probiotics which are naturally resistant to several antibiotics and sulfonamides to use in this discovery. Dr. M.S. Reddy has studied and confirmed through thorough research that, the antibiotic resistance was not coded by the plasmids but by the chromosol genes, thus it is safer to use these Multiple Mixed Strain Probiotics to eliminate the free exchange of plasmids to the pathogenic bacteria [5]. The Multiple Mixed Strain Probiotic Strains belonging to different genera and species (with varied physiological characteristics) were grown separately in selected nutritionally balanced media, not only to maximize their cell numbers and their single cell morphology (as opposed to chain formation), but also to significantly improve the quantity of their end products of growth i.e. immunomodulins, bacteriocins, and specific and nonspecific bio-active peptides etc. Such individually grown single strain probiotics were blended in fixed proportions and frozen using liquid nitrogen, to be used as therapeutic agents administered through oral route [3]. Unlike the popular thinking, the significant feature of the discovery is that the probiotic bacterial cultures alone (without their prior growth end products) did not cure the hospital acquired infections. However, the multiple growth end products of these Multiple Mixed strain Probiotics (immunomodulins) along with the active probiotic bacteria significantly cured the nosocomial infections [6].

It was also determined and confirmed that the multiple antibiotic resistant pathogenic bacteria i.e. C. diff etc. was initially inhibited (in vivo) through the immunodolation exerted by the Multiple Mixed Strain Probiotic growth end products along with the dendritic cells picked up probiotic cell wall antigens. The immunomodulation induced by probiotics was through production of IL-10, retinoic acid, TGF-Beta with resultant well balanced activation of T-reg cells [7]. The excess inflammation caused due to immune stimulation as a response to the pathogenic bacterial peptides of C. diff bacteria, through activation of Th-1, Th-2, Th-17 and excess production of IGA, was reduced predominantly through activation of T-reg cells stimulated by Multiple Mixed Strain Probiotics and their immunomodulins, used in this discovery [7]. As a second step (after establishment of positive immunomodulation in vivo), the live probiotic cells in the intestinal tract lumen started directly inhibiting the pathogenic C diff organisms etc. Thus, this invention is novel in that the primary inhibition of the pathogenic bacteria is indirectly due to the previously produced active immunomodulins of the probiotic bacteria, followed by the secondary direct physical inhibition due to live probiotic bacteria in the Lumen, through nutritional competency, production of organic acids, bacteriocins, and finally through stimulation and maintenance of component balance of other non-pathogenic saprophytic intestinal microbiota [5,7]. The bacteriological analysis of patient’s feces, after the multiple probiotic infusion treatment, revealed total absence of pathogenic C. diff organisms, and at the same time significant elevation of intestinal microbiota (in comparison to the beginning of treatment) by two logs (determined by combination of anaerobic as well as aerobic total bacterial counts). In addition, it was proven that the individual strains used in the Multiple Mixed Strain Probiotic Therapy did adhere to the intestinal epithelial cells of the host, which was confirmed by biopsy and subsequent microbiological testing including strain specific phage typing. While conducting the practical clinical trials using Dr. M.S. Reddy’s Multiple Mixed Strain Probiotics to prevent or cure hospital acquired infections, Dr. Reddy came up with another novel breakthrough serendipitous discovery to cure cancer with a significantly greater efficiency, when such Multiple Mixed Strain Probiotic Therapy is used as an adjuvant in combination with standard cancer therapies, including the immune checkpoint therapy. This breakthrough discovery has been published in 2018 [7]. Dr. M.S. Reddy’s discovery is termed as “Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy”. This Adjuvant Cancer Therapy establishes immune tolerance and thus helps the primary cancer therapy to be most effective, with least or no side effects. It also significantly reduced the relapse of cancer, which was proven through multiple community based clinical trials. This was accomplished through positive maintenance of the cancer patients gut microbiota and their microbiome, thus establishing the proper immunomodulation which results in significant reduction of immune stimulation and inflammation. This in turn established a positive immune tolerance, which is the prime requisite to synergistically improve the efficiency of the standard cancer therapies. This explains why most of the previous cancer therapies were not effective to cure cancer with greater efficiency (of not more than 20 percent).

The clinical tests (with regard to treatment or prevention of nosocomial infections) clearly proved the following, using the procedure outlined in our earlier publication [1,5]. The antibiotic therapy (using vancomycin and bacitracin) alone could not cure the hospital acquired infections; probiotic therapy by itself showed significant progress even after one week treatment followed by total cure by 4th week; prior administration of probiotics (prior to hospitalization) for a period of 2 weeks, significantly reduced C. diff infection; the subjects who were given preventive probiotics for a period of 3 weeks (prior to hospitalization) did not pick up any C. diff infection, during and after hospitalization; combination of antibiotic and Multiple Mixed Strain Probiotic Therapy cured the C. diff infection in two weeks compared to probiotic therapy alone (which took 4 weeks) and antibiotic therapy alone (which could not cure even after, and beyond 4 weeks of treatment). Although it was a serendipitous discovery, later several planned community based clinical trials conducted using Multiple Mixed Strain Probiotic Therapy as an Adjuvant Cancer Therapy, along with the immune checkpoint therapy and other standard cancer therapies, proved that cancer was cured with 60% efficiency, as opposed to 20% by immune checkpoint therapy and other standard therapies alone. Unlike the pharmaceutical cancer drugs, Multiple Mixed Strain Probiotics come under nutritional supplements, as per the Code of Federal Regulations, and thus are highly economical and affordable and can be used without any major governmental regulations [2].

Conclusion

Dr. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy, proven through extensive basic research and continued multiple practical community based clinical trials, found to be the best complementary therapy to cure cancer along with the use of immune checkpoint therapy and other traditional cancer therapies. Ultimately, this could be the answer to prevent or treat cancer with 80 to 100% accuracy with no immune related side effects and with least relapse. Thus, cancer can be treated using such a complementary adjuvant probiotic therapy, along with any chosen conventional cancer therapy, as a choice therapy than a chance therapy, to save lives of over 9 million people in the world per year. It is the first time in the world, where a missing link in the successful treatment of cancer has been discovered, and immense credit should go to this breakthrough medical discovery. This discovery can be further improved to develop customized treatment by taking into account the genetics of the cancer patients to cure several cancers. Multiple Mixed Strain Probiotic Therapy, coupled with positive nutritional and life style modifications, may also serve as a preventive aid to eliminate or reduce cancer epidemic by maintaining the healthy microbiota and their microbiome.

 

https://lupinepublishers.com/pharmacology-clinical-research-journal/fulltext/genesis-evaluation-and-progression-of-a-breakthrough-discovery-to-efficiently-cure-cancer.ID.000121.php

https://lupinepublishers.com/pharmacology-clinical-research-journal/pdf/LOJPCR.MS.ID.000121.pdf

For more Lupine Publishers Open Access Journals Please visit our website: https://lupinepublishersgroup.com/

For more Pharmacology & Clinical Research Please Click
Here: https://lupinepublishers.com/pharmacology-clinical-research-journal/

To Know more Open Access Publishers Click on Lupine Publishers

Follow on Linkedin : https://www.linkedin.com/company/lupinepublishers
Follow on Twitter   :  https://twitter.com/lupine_online